{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.30","value":"37.69"},{"groupId":"OG001","spread":"65.52","value":"61.31"}]}],"title":"Cycle 8 (n = 174, 170)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"75.03","value":"30.35"},{"groupId":"OG001","spread":"81.23","value":"49.47"}]}],"title":"Cycle 9 (n = 171, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.64","value":"28.44"},{"groupId":"OG001","spread":"73.03","value":"47.27"}]}],"title":"Cycle 10 (n = 164, 160)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.28","value":"28.77"},{"groupId":"OG001","spread":"66.80","value":"46.70"}]}],"title":"Cycle 11 (n = 164, 157)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.97","value":"28.80"},{"groupId":"OG001","spread":"68.74","value":"44.72"}]}],"title":"Cycle 12 (n = 160, 150)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.04","value":"28.84"},{"groupId":"OG001","spread":"67.67","value":"44.32"}]}],"title":"Cycle 13 (n = 157, 150)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.61","value":"28.09"},{"groupId":"OG001","spread":"67.97","value":"43.32"}]}],"title":"Cycle 14 (n = 153, 147)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.69","value":"28.19"},{"groupId":"OG001","spread":"67.92","value":"44.11"}]}],"title":"Cycle 15 (n = 148, 143)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.19","value":"28.05"},{"groupId":"OG001","spread":"64.32","value":"42.96"}]}],"title":"Cycle 16 (n = 150, 145)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.51","value":"28.24"},{"groupId":"OG001","spread":"65.67","value":"42.82"}]}],"title":"Cycle 17 (n = 149, 143)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.06","value":"28.59"},{"groupId":"OG001","spread":"68.56","value":"44.79"}]}],"title":"Cycle 18 (n = 143, 132)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.26","value":"27.75"},{"groupId":"OG001","spread":"69.02","value":"43.69"}]}],"title":"Cycle 19 (n = 138, 131)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"170"}],"units":"Participants"}],"description":"Stage I and II (maintenance): D29 of Cy8 (induction; 1 Cy=4 weeks), predose (within 2 hr) on D1 of Cy9 to 19 (maintenance Cy1 to 12 \\[1 Cy=8 weeks\\]; up to data cutoff of 11 Jan 2016 \\[up to 6 years\\])","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"ITT Population. Here, number of participants analyzed = participants evaluable for the outcome measure. Here \"n\" = number of participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Stage I and II (maintenance): Predose (within 2hr) up to data cutoff of 11 Jan 2016 [up to 6 years]) (See detailed timeframe in Outcome Measure description)","title":"Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle","type":"SECONDARY","unitOfMeasure":"mcg/mL"}